FDA approves Gemtuzumab Ozogamicin for treatment of acute myeloid leukemia

September 1, 2017 – The U.S. Food and Drug Administration today approved gemtuzumab ozogamicin for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved gemtuzumab ozogamicin for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) … (leggi tutto)